GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that the U.S. Patent
and Trademark Office has issued a composition of matter patent (No.
9,109,002), entitled “E-Selectin Antagonist Compounds, Compositions and
Methods of Use,” which provides coverage for the chemical structure of
GlycoMimetics’ clinical product candidate GMI-1271. Based upon data from
preclinical studies, GMI-1271, which is a novel and proprietary
E-selectin antagonist, has the potential to synergize with chemotherapy
to improve cancer cell killing. It may also address both metastasis
(cancer’s spread) and complications of chemotherapy including
neutropenia and mucositis. Applications are pending for patents outside
of the United States.
“This patent issuance represents an important step for GlycoMimetics and
our clinical product candidate, GMI-1271, as it provides key
intellectual property protection,” said Rachel
King, Chief Executive Officer, GlycoMimetics. “We are initially
exploring the clinical use of GMI-1271 in hematologic malignancies
following the successful
completion of a Phase 1 study in healthy volunteers late last year.”
GlycoMimetics began dosing patients in May 2015 in a Phase 1/2,
open-label multicenter study designed to determine safety,
pharmacokinetics and efficacy of GMI-1271 in combination with
chemotherapy in male and female adult patients with acute myeloid
leukemia (AML).
Data from preclinical studies describing the activity of GMI-1271 were
selected for oral presentations at the annual meeting of the American
Society of Hematology (ASH) in both 2013 and 2014.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role. GlycoMimetics entered into an exclusive license
agreement with Pfizer for rivipansel in October 2011. Under the license
agreement, Pfizer is responsible for the clinical development,
regulatory approval and potential commercialization of rivipansel.
GlycoMimetics’s wholly-owned drug candidate (GMI-1271) for AML and other
blood disorders is also in clinical trials. Glycomimetics are molecules
that mimic the structure of carbohydrates involved in
important biological processes. Using its expertise in carbohydrate
chemistry and knowledge of carbohydrate biology, GlycoMimetics is
developing a pipeline of glycomimetic drug candidates that inhibit
disease-related functions of carbohydrates, such as the roles they play
in inflammation, cancer and infection. Learn more at www.glycomimetics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding the
clinical development of GMI-1271. Actual results may differ materially
from those in these forward-looking statements. For a further
description of the risks associated with these statements, as well as
other risks facing GlycoMimetics, please see the risk factors described
in the Company’s quarterly report on Form 10-Q that was filed with the
U.S. Securities and Exchange Commission on August 6, 2015, and other
filings the Company makes with the SEC from time to time.
Forward-looking statements speak only as of the date of this release,
and GlycoMimetics undertakes no obligation to update or revise these
statements, except as may be required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150831006192/en/
Copyright Business Wire 2015